Jafron Biomedical, a leading enterprise in the hemoadsorption industry announces that Mr. Jean Paul Menneguerre has taken up the new role as the Senior Head of the EMEA markets to facilitate its business growth in EMEA countries.

Mr. Jean Paul Menneguerre, a global expert in the acute blood purification area for more than 30 years, has joined Jafron Biomedical as Global Senior Consultant since January 2021, devising Jafron’s global marketing strategies and clinical activities. 

From January 2023, taking up the critical role of the EMEA markets, Mr. Menneguerre will be the one who leads the whole team to achieve the sales target, implementation of marketing activities, and R&D support in EMEA countries. His new role also means Jafron will strengthen its efforts to explore EMEA markets. 

Jafron's innovative hemoperfusion therapies are currently available in more than 80 countries and regions worldwide. In June 2021, Jafron established a MOST (Multi-Organ Support Therapy) Advisory Board composed of 6 world-class clinical researchers and intensive care experts. In the coming years, Jafron’s increasing influence in the world’s hemoadsorption industry will be paired with a commitment to innovation and knowledge sharing in the healthcare community and it will provide medical researchers and physicians worldwide with more efficient therapies for meeting the rapid development of the blood purification industry.